Table 1.
The point-scoring tools
| Yes | No | |
|---|---|---|
| A. Prediction of co-amoxiclav resistance (incorporating electronic-prescribing data) | ||
| previous co-amoxiclav prescription | +3 | −1 |
| comorbidity: other inflammatory condition of skin; chronic ulcer of skin; other skin disorders | +1 | −1 |
| previous co-amoxiclav susceptibility | −2 | 0 |
| comorbidity: septicaemia, shock | +3 | 0 |
| previous co-amoxiclav resistance | +7 | −1 |
| B. Prediction of piperacillin/tazobactam resistance (incorporating electronic-prescribing data) | ||
| sample type: blood | −2 | 0 |
| previous co-amoxiclav susceptibility | –1 | 0 |
| previous co-amoxiclav resistance | +4 | –1 |
| comorbidity: diabetes mellitus without complication | +2 | –1 |
| previous piperacillin/tazobactam resistance | +7 | –1 |
| C. Prediction of co-amoxiclav resistance (excluding electronic-prescribing data) | ||
| comorbidity: mental retardation, senility and organic mental disorders | +2 | 0 |
| consultant specialty: general medicine | +1 | –1 |
| previous co-amoxiclav susceptibility | –2 | 0 |
| comorbidity: septicaemia, shock | +3 | 0 |
| previous co-amoxiclav resistance | +7 | –1 |
| D. Prediction of piperacillin/tazobactam resistance (excluding electronic-prescribing data) | ||
| comorbidity: COPD and bronchiectasis | +2 | 0 |
| comorbidity: skin and subcutaneous tissue infections | +3 | 0 |
| previous co-amoxiclav resistance | +5 | –1 |
| number of comorbidities >5 | +1 | –1 |
| previous piperacillin/tazobactam resistance | +8 | –1 |
The presence of a factor adds the value indicated in the ‘Yes’ column to the patient’s score, the absence the addition of the value in the ‘No’ column. If the resulting total reaches a pre-determined threshold, the patient is considered at risk of resistance to that antibiotic. In this study, the threshold was set at a point producing a level of ‘under’ or 'over'-prescribing similar to that of medical staff.